Literature DB >> 11413523

Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival.

P I Haigh1, P H Ituarte, H S Wu, P A Treseler, M D Posner, J M Quivey, Q Y Duh, O H Clark.   

Abstract

BACKGROUND: The prognosis of anaplastic thyroid carcinoma (ATC) has been dismal. The objective of this study was to identify prognostic factors in patients who had prolonged survival.
METHODS: Patients with ATC were identified from a computer database at a tertiary referral center. Univariate and multivariate analyses for survival differences were performed using the Kaplan-Meier log-rank statistic and the Cox proportional hazards model, respectively.
RESULTS: Of the 33 evaluable patients, median survival was 3.8 months. Median age was 69 years. Prior goiter was present in 6 patients (18%), and 6 (18%) had prior thyroid carcinoma. Median tumor size was 6 cm, and 12 (36%) had adjacent well-differentiated carcinoma. Of the 26 patients who underwent neck exploration, 8 patients were potentially cured and received postoperative chemotherapy and irradiation; 4 (50%) were surgically macroscopically free of disease, and 4 (50%) patients had minimal residual disease after total thyroidectomy and resection of tumor adherent to adjacent structures. Four of these 8 patients survived longer than 2 years; their 5-year survival estimate was 50%. Eighteen patients underwent palliative resection of neck disease, leaving macroscopic residual disease or distant metastases; postoperative adjuvant chemotherapy and irradiation were administered in 16 of these 18 patients. Seven patients were treated with only chemotherapy and irradiation. In patients treated with potentially curative resection, median survival was 43 months compared with 3 months with palliative resection (P =0.002); the median survival of 3.3 months with only chemotherapy and irradiation was no different than palliative resection (P =0.63). No association was found between survival and age, prior goiter, prior thyroid carcinoma, adjacent differentiated carcinoma, or tumor size.
CONCLUSIONS: Although the prognosis of most patients with ATC continues to be poor, complete resection of ATC combined with postoperative adjuvant chemotherapy and irradiation resulted in long-term survival, even with persistent minimal disease that remained on vital structures. An aggressive attempt at maximal tumor debulking followed by adjuvant therapy was found to be warranted in patients with localized ATC. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11413523

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  60 in total

1.  Dyspnea as a prognostic factor in anaplastic thyroid carcinoma.

Authors:  Lauren Tashima; Ron Mitzner; Saima Durvesh; David Goldenberg
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-09-20       Impact factor: 2.503

Review 2.  Anaplastic thyroid carcinoma.

Authors:  P I Haigh
Journal:  Curr Treat Options Oncol       Date:  2000-10

3.  Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.

Authors:  Iwao Sugitani; Akira Miyauchi; Kiminori Sugino; Takahiro Okamoto; Akira Yoshida; Shinichi Suzuki
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 4.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

5.  Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.

Authors:  Todd A Pezzi; Abdallah S R Mohamed; Tommy Sheu; Pierre Blanchard; Vlad C Sandulache; Stephen Y Lai; Maria E Cabanillas; Michelle D Williams; Christopher M Pezzi; Charles Lu; Adam S Garden; William H Morrison; David I Rosenthal; Clifton D Fuller; G Brandon Gunn
Journal:  Cancer       Date:  2016-12-27       Impact factor: 6.860

Review 6.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

Review 7.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

8.  Anaplastic thyroid carcinoma: a therapeutic dilemma.

Authors:  Hang-Seok Chang; Kee-Hyun Nam; Woung Youn Chung; Cheong Soo Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

9.  Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers.

Authors:  David Tai; Donald Poon
Journal:  J Oncol       Date:  2010-08-24       Impact factor: 4.375

Review 10.  Anaplastic thyroid carcinoma: an overview.

Authors:  Wendy R Cornett; Anand K Sharma; Terry A Day; Mary S Richardson; Rana S Hoda; Jon A van Heerden; Jyotika K Fernandes
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.